CONCLUSION: This study establishes AICD as a clinically relevant metabolic cell death mechanism in NSCLC and identifies SLC7A5, SLC2A1, CAV1, and SPP1 as potential prognostic biomarkers and therapeutic targets. This evidence concerns the gene SLC7A5 and non-small cell lung carcinoma.